1 / 42

Fetal Growth Restriction

Fetal Growth Restriction. Steven R. Allen, MD Scott & White Clinic TAMU-HSC. Educational Objectives. Review epidemiology and significance of fetal growth restriction (FGR) Know etiologies (= risk factors) Discuss screening strategies for FGR

thao
Télécharger la présentation

Fetal Growth Restriction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fetal Growth Restriction Steven R. Allen, MD Scott & White Clinic TAMU-HSC

  2. Educational Objectives • Review epidemiology and significance of fetal growth restriction (FGR) • Know etiologies (= risk factors) • Discuss screening strategies for FGR • Evaluate the role for Doppler velocimetry in the diagnosis & mgmt of FGR • Develop treatment strategies for FGR

  3. Arbitrary threshold for “growth restriction” Weight Gest Age, weeks

  4. Variables affecting normal fetal growth* • Gender • Ethnicity • Number of fetuses • Altitude • Parental phenotype * generally not accounted for in growth curves

  5. Significance of fetal growth restriction (FGR) • 3-10% of newborns are “growth restricted” • associated morbidities • intrapartum FHR abnormalities • cord blood acidemia • cesarean delivery • neonatal hypoglycemia, hypothermia, and hyperbilirubinemia • 1/4 stillbirths are SGA

  6. FGR: neonatal morbidities27-32 wks gestation NS* % NS *RDS: not benefited by FGR AJ Perinat 2000;17:187

  7. Long term implications of FGR IQ • Outcome related to etiology - worse for aneuploidy, viral infxn • Catch-up growth common • Adult risks: HTN, hypercholesterolemia • Minimal reduction in IQ not predictive of academic achievement J Pediatr 2001;138:87

  8. Long term implications of FGR RR LBW vs heaviest Barker “thrifty phenotype” hypothesis • Fetus adapts to malnutrition • Cephalized blood flow • Metabolic programming beneficial to malnourished fetus is detrimental if adequate nutrition later available • Unknowns • Molecular basis • Relative roles of genetic & environmental factors Ozanne. Online review. 9/12/02. http://tem.trends.com

  9. Pathophysiology of FGR Cellular Hyperplasia Cellular Hypertrophy “symmetric” “asymmetric” 1 3 Trimester

  10. Etiology of FGR

  11. Etiology of FGR • “Symmetric”: • infection (<5%) • malformation • aneuploidy • low mat wt, wt gain • multiple gest • XR exposure

  12. Etiology of FGR • “Symmetric”: • tobacco • alcohol • substance abuse • teratogens

  13. Etiology of FGR “Constitutionally small” Placental mosaicism (up to 1/4) • “Asymmetric”: • HTN • renal dis • thrombophilia • hypoxia • anemia • advanced DM • malnutrition

  14. Prior IUGR as a predictor of subsequent stillbirth OR Swedish birth registry 1983-1997 Wks gest age of prior SGA birth Surkan. NEJM 2004;350;777-85

  15. Defects in “classic” model of FGR subsets • Many preterm fetuses with growth restriction secondary to maternal HTN have symmetric FGR • Many aneuploid fetuses have asymmetric growth (“head sparing”)

  16. Classification of FGR symmetric asymmetric

  17. Abnormal metabolic parametersseen in some populations with FGR • Most FGR fetuses have normal PO2 & PCO2 • Hct & Hgb usually normal, with high MCV and RDW (erythropoeisis/reticulocytosis) • Inconsistent hypoglycemia (& hypo-insulinemia) • Increased ratio of non-essential:essential AA • Hypertriglyceridemia • Thrombocytopenia

  18. Screening for FGR Etiologies = risk factors • Fetal • Maternal-fetal • Maternal • Idiopathic

  19. Screening for FGR Physical exam • Serial fundal height: between 18-30 weeks, FH(+/- 2-3 cm) = EGA in weeks • sensitivity for FGR = 40-67% • false pos rate = 50%

  20. Screening for FGR Ultrasonography • EFW • Abdominal circumference • Head:abdomen ratio • Serial measurements (rate of growth) • Amniotic fluid volume Anatomic survey indicated if FGR detected

  21. Screening for FGR Ultrasonography • 3rd TM AC sensitivity for FGR = 80% (no different than sensitivity of FH) • Reserve US for those pts at risk for FGR: • risk factors • S<D • prior SGA ACOG Prac Bull #12, 1/2000

  22. Doppler velocimetry Screening for FGR • sensitivity in Low Risk population: 15-30% • sensitivity in Hi Risk population: 75-95% • commonly associated with FGR, but not diagnositic • NOT uniquely helpful

  23. Doppler velocimetry: S/D ratio S/D = 3.1

  24. Doppler velocimetry Management of FGR • Umbilical artery: S/D ratio increases with placental resistance

  25. Umbilical artery in FGR

  26. Doppler velocimetry Management of FGR • Umbilical artery: S/D ratio increases with placental resistance • Middle cerebral artery: S/D ratio decreases with cephalization (“head sparing”)

  27. Middle cerebral artery in FGR

  28. Doppler velocimetry Management of FGR • Umbilical artery: S/D ratio increases with placental resistance • Middle cerebral artery: S/D ratio decreases with cephalization (“head sparing”) • Umbilical vein: becomes pulsatile with heart failure

  29. Umbilical vein in extreme FGR

  30. Doppler velocimetry Management of FGR • Umbilical artery: S/D ratio increases with placental resistance • Middle cerebral artery: S/D ratio decreases with cephalization (“head sparing”) • Umbilical vein: becomes pulsatile with heart failure • Ductus venosus: decreased forward velocity or reversal of “a” wave (atrial kick) • Changes typically occur in this sequence prompting a logical screening sequence

  31. Ductus venosus in extreme FGR “a” wave

  32. FGR example 1risk factor: tobacco Weight Gest Age, weeks Umb artery S/D nl

  33. FGR example 1: mgmt • d/c tobacco • serial US • biophysical testing and FACs • delivery plan?

  34. Umb art S/D predicts risk of neonatal morbidity % J US Med 2000;19:661

  35. FGR example 2risk factor: CHTN Weight Gest Age, weeks Umb artery S/D elevated

  36. FGR example 2: mgmt • MCA S/D ratio - minimally decreased; normal umb venous flow pattern • R/O PIH • serial US • biophysical testing and FACs • delivery plan?

  37. Interventions with UNproven efficacy • nutrient treatment • zinc supplementation • calcium supplementation • plasma volume expansion • oxygen • heparin • aspirin

  38. FGR example 3risk factor: AMA Weight Gest Age, weeks Oligohydramnios; umb art AED; MCA S/D low; umb vn pulsatile

  39. FGR example 3: mgmt • Continuous monitoring • Corticosteroids • Delivery after 24 hrs if stable

  40. Considerations for delivery • Non-reassuring acute fetal status • Cessation of growth over 2-4 wks • Oligohydramnios • “When extrauterine survival is likely in the presence of significantly abnormal antenatal testing” ACOG Prac Bull #12, 1/2000

  41. FGR: Summary Recommendations(Level A) • Umbilical artery velocimetry is useful to reduce perinatal death once FGR is suspected or diagnosed • No specific treatments (nutritional supplements, oxygen, heparin, ASA, volume expansion, or antihypertensive agents) effectively prevent or treat FGR ACOG Prac Bull #12, 1/2000

  42. FGR: Summary Recommendations(Level C) • Antepartum surveillance should be instituted when extrauterine survival is possible • No particular form of antenatal testing is superior • Screen low-risk pts for FGR using physical exam • US is appropriate screen for FGR in hi-risk pts ACOG Prac Bull #12, 1/2000

More Related